CSL Behring International Trial Shows Clinical Efficacy of Recombinant Fusion
Protein Linking Coagulation Factor IX with Albumin (rIX-FP) for Once Weekly
Prophylaxis in Patients with Severe Hemophilia B
Results of Phase I/II PROLONG-9FP trial program also demonstrate efficacy in
treatment of bleeding episodes and improved pharmacokinetics of rIX-FP
compared to current treatment options; recombinant albumin fusion platform
forms basis of innovation
AMSTERDAM, July 3, 2013
AMSTERDAM, July 3, 2013 /PRNewswire/ --Data presented by CSL Behring today
showed clinical efficacy of a once-weekly dosing regimen of recombinant fusion
protein linking coagulation Factor IX with albumin (rIX-FP). Results of the
study were presented during an oral session at the International Society on
Thrombosis and Haemostasis (ISTH) congress in Amsterdam.
(Logo: http://photos.prnewswire.com/prnh/20130627/NY39350LOGO )
CSL Behring, in collaboration with its parent company, CSL Limited (ASX: CSL),
is developing rIX-FP for the prophylaxis and treatment of bleeding episodes in
patients with hemophilia B as part of the PROLONG-9FP clinical study program.
"Hemophilia B is characterized by factor IX deficiency, which prevents normal
blood clotting. People with this condition require factor IX infusions two to
three times a week to achieve a significant reduction in bleeding," said
Professor Uri Martinowitz, Director of the Institute of Thrombosis and
Hemostasis and the Israeli National Hemophilia Center at Chaim Sheba Medical
Center in Tel Hashomer, Israel. "This trial showed that less frequent
infusions were needed with CSL Behring's investigational rIX-FP compared to
currently available FIX products used on-demand or prophylactically to prevent
or treat bleeding episodes."
The trial enrolled 17 hemophilia B patients, 13 of whom received weekly
prophylactic treatment for approximately 11 months, and four of whom received
on-demand treatment only when bleeding occurred. All prophylaxis patients
maintained weekly treatment for the entire study, with mean and median
annualized spontaneous bleeding rates of 1.26 and 1.13, respectively. All
bleeding was treated successfully with two or fewer infusions of rIX-FP, with
95.3 percent of events treated with a single infusion.
Following a single infusion of 25 IU/kg rIX-FP, the mean FIX activity level
was 3.8 percent and 2.7 percent above baseline at day 7 and 14, respectively,
and the half-life (time taken for half of the treatment to be eliminated or
metabolized) of rIX-FP was 94 hours.
"We are very encouraged by these results demonstrating efficacy of a
once-weekly infusion of our investigational rIX-FP, as we selected albumin as
the ideal genetic fusion partner for our recombinant Factor IX due to its
inherently long half-life and good tolerability profile," said Dr. Stefan
Schulte, Vice President of Research and Development, CSL Behring. "We look
forward to advancing rIX-FP in clinical trials as we are committed to
developing recombinant factor therapies that have the potential to improve
compliance and ease prophylaxis. This may, in turn, improve the quality of
life for people with hemophilia B."
About the Phase I/II Study
The Phase I/II study was an open-label, multicenter, clinical study of rIX-FP
in previously treated patients with severe hemophilia B (FIX ≤ 2%), and part
of CSL Behring's PROLONG - 9FP clinical developmental program.
The objectives of the study were to evaluate the prevention of bleeding
episodes during once weekly prophylaxis and to assess the hemostatic efficacy
of rIX-FP for the treatment of bleeding, in addition to safety and
pharmacokinetic (PK) assessments. The study consisted of a 10 to 14 day PK
evaluation period, and a three to 12 month safety and efficacy evaluation
period, during which patients received either on-demand or prophylaxis
treatment. More information about the study design can be found at
CSL Behring engineered rIX-FP to extend the half-life of factor IX through
genetic fusion with recombinant albumin. CSL Behring selected albumin as the
ideal recombinant genetic fusion partner for its coagulation factor proteins
due to its long physiological half-life. In addition, albumin has been shown
to have a good tolerability profile, low potential for immunogenic reactions
and a well-known mechanism of clearance compared to some other technologies.
The cleavable linker connecting recombinant factor IX and recombinant albumin
has been specifically designed to preserve the native function of the
coagulation factor in the fusion protein, while benefiting from recombinant
albumin's long physiological half-life.
Hemophilia is an inherited bleeding disorder characterized by prolonged or
spontaneous bleeding, especially into the muscles and joints. In nearly all
cases, it affects only males. The disease is caused by deficient or defective
blood coagulation proteins known as factor VIII or IX. The most common form of
the disease is hemophilia A, or classic hemophilia, in which the clotting
factor VIII is either deficient or defective. Hemophilia A affects
approximately 1 in 5,000 to 10,000 people. Hemophilia B is characterized by
deficient or defective factor IX. Hemophilia B affects approximately 1 in
25,000 to 50,000 people. The recommended treatment for patients who are factor
deficient is to treat by replacement factor therapy.
About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed
to saving lives and improving the quality of life for people with rare and
serious diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are used around the world to treat coagulation disorders
including hemophilia and von Willebrand disease, primary immune deficiencies,
hereditary angioedema and inherited respiratory disease, and neurological
disorders in certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent hemolytic
diseases in the newborn. CSL Behring operates one of the world's largest
plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL
Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne,
Australia. For more information, visit http://www.cslbehring.com/.
Sheila A. Burke, Director, Communications & Public Relations
Worldwide Commercial Operations
SOURCE CSL Behring
Press spacebar to pause and continue. Press esc to stop.